ORALLY ADMINISTRABLE LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, WITH ACE INHIBITORS FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DENSITY LIPOPROTEIN
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 10, 2014
app pub date -
Feb 5, 2014
filing date -
Nov 7, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention proposes the combination of reduced glutathione in a liposome (liposomal reduced glutathione) with a specified concentration of reduced glutathione within the liposome for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with ACE inhibitors in order to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with lisinopril in particular.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully